• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超级增强子在消化系统肿瘤治疗靶点中的新兴作用。

The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors.

机构信息

Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410007, PR China.

Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410007, PR China.

出版信息

Int J Biol Sci. 2023 Jan 22;19(4):1036-1048. doi: 10.7150/ijbs.78535. eCollection 2023.

DOI:10.7150/ijbs.78535
PMID:36923930
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10008685/
Abstract

Digestive system tumors include malignancies of the stomach, pancreas, colon, rectum, and the esophagus, and are associated with high morbidity and mortality. Aberrant epigenetic modifications play a vital role in the progression of digestive system tumors. The aberrant transcription of key oncogenes is driven by super-enhancers (SEs), which are characterized by large clusters of enhancers with significantly high density of transcription factors, cofactors, and epigenetic modulatory proteins. The SEs consist of critical epigenetic regulatory elements, which modulate the biological characteristics of digestive system tumors including tumor cell identity and differentiation, tumorigenesis, environmental response, immune response, and chemotherapeutic resistance. The core transcription regulatory loop of the digestive system tumors is complex and a high density of transcription regulatory complexes in the SEs and the crosstalk between SEs and the noncoding RNAs. In this review, we summarized the known characteristics and functions of the SEs in the digestive system tumors. Furthermore, we discuss the oncogenic roles and regulatory mechanisms of SEs in the digestive system tumors. We highlight the role of SE-driven genes, enhancer RNAs (eRNAs), lncRNAs, and miRNAs in the digestive system tumor growth and progression. Finally, we discuss clinical significance of the CRISPR-Cas9 gene editing system and inhibitors of SE-related proteins such as BET and CDK7 as potential cancer therapeutics.

摘要

消化系统肿瘤包括胃、胰腺、结肠、直肠和食管的恶性肿瘤,其发病率和死亡率都很高。异常的表观遗传修饰在消化系统肿瘤的进展中起着至关重要的作用。关键癌基因的异常转录是由超级增强子(SEs)驱动的,SEs 的特征是具有大量增强子簇,转录因子、共因子和表观遗传调节蛋白的密度显著升高。SEs 由关键的表观遗传调节元件组成,调节消化系统肿瘤的生物学特征,包括肿瘤细胞的身份和分化、肿瘤发生、环境反应、免疫反应和化疗耐药性。消化系统肿瘤的核心转录调控环路很复杂,SEs 中的转录调控复合物密度很高,SEs 与非编码 RNA 之间存在串扰。在这篇综述中,我们总结了 SEs 在消化系统肿瘤中的已知特征和功能。此外,我们还讨论了 SE 在消化系统肿瘤中的致癌作用和调控机制。我们强调了 SE 驱动基因、增强子 RNA(eRNA)、lncRNA 和 miRNA 在消化系统肿瘤生长和进展中的作用。最后,我们讨论了 CRISPR-Cas9 基因编辑系统和 BET 和 CDK7 等 SE 相关蛋白抑制剂作为潜在癌症治疗药物的临床意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca1/10008685/8d0078210d47/ijbsv19p1036g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca1/10008685/ccefbfef631d/ijbsv19p1036g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca1/10008685/402beb51faa3/ijbsv19p1036g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca1/10008685/8d0078210d47/ijbsv19p1036g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca1/10008685/ccefbfef631d/ijbsv19p1036g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca1/10008685/402beb51faa3/ijbsv19p1036g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ca1/10008685/8d0078210d47/ijbsv19p1036g003.jpg

相似文献

1
The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors.超级增强子在消化系统肿瘤治疗靶点中的新兴作用。
Int J Biol Sci. 2023 Jan 22;19(4):1036-1048. doi: 10.7150/ijbs.78535. eCollection 2023.
2
Super-enhancers complexes zoom in transcription in cancer.超级增强子复合物在癌症转录中放大。
J Exp Clin Cancer Res. 2023 Jul 28;42(1):183. doi: 10.1186/s13046-023-02763-5.
3
Super enhancer lncRNAs: a novel hallmark in cancer.超级增强子长链非编码 RNA:癌症的一个新标志。
Cell Commun Signal. 2024 Apr 2;22(1):207. doi: 10.1186/s12964-024-01599-6.
4
[Research progress of super enhancer in cancer].[超级增强子在癌症中的研究进展]
Yi Chuan. 2019 Jan 20;41(1):41-51. doi: 10.16288/j.yczz.18-152.
5
Super-enhancers: critical roles and therapeutic targets in hematologic malignancies.超级增强子:血液系统恶性肿瘤中的关键作用和治疗靶点。
J Hematol Oncol. 2019 Jul 16;12(1):77. doi: 10.1186/s13045-019-0757-y.
6
The emerging role of super enhancer-derived noncoding RNAs in human cancer.超级增强子衍生的非编码 RNA 在人类癌症中的新兴作用。
Theranostics. 2020 Sep 2;10(24):11049-11062. doi: 10.7150/thno.49168. eCollection 2020.
7
Super-enhancers and novel therapeutic targets in colorectal cancer.结直肠癌中的超级增强子和新的治疗靶点。
Cell Death Dis. 2022 Mar 11;13(3):228. doi: 10.1038/s41419-022-04673-4.
8
Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.解析超级增强子驱动的转录依赖性,揭示了 3 组亚型髓母细胞瘤的新治疗策略和靶点。
J Exp Clin Cancer Res. 2022 Oct 22;41(1):311. doi: 10.1186/s13046-022-02506-y.
9
Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets.前列腺癌中的超级增强子:转录紊乱与治疗靶点
NPJ Precis Oncol. 2020 Nov 19;4(1):31. doi: 10.1038/s41698-020-00137-0.
10
Super-enhancers: A new frontier for glioma treatment.超级增强子:胶质瘤治疗的新前沿。
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188353. doi: 10.1016/j.bbcan.2020.188353. Epub 2020 Feb 26.

引用本文的文献

1
Functional characteristics of fresh antitumor immune interferer GDF-15 in multiple cancers.新型抗肿瘤免疫干扰因子GDF-15在多种癌症中的功能特性
Sci Rep. 2025 Aug 22;15(1):30864. doi: 10.1038/s41598-025-16737-4.
2
Enhancer regulation in cancer: from epigenetics to mA RNA modification.癌症中的增强子调控:从表观遗传学到 mA RNA 修饰
Arch Pharm Res. 2025 Aug 19. doi: 10.1007/s12272-025-01561-1.
3
Research progress on m6A and drug resistance in gastrointestinal tumors.胃肠道肿瘤中m6A与耐药性的研究进展

本文引用的文献

1
Integrating the Epigenome and Transcriptome of Hepatocellular Carcinoma to Identify Systematic Enhancer Aberrations and Establish an Aberrant Enhancer-Related Prognostic Signature.整合肝细胞癌的表观基因组和转录组以识别系统性增强子畸变并建立异常增强子相关的预后特征。
Front Cell Dev Biol. 2022 Mar 1;10:827657. doi: 10.3389/fcell.2022.827657. eCollection 2022.
2
RNA Helicase DHX37 Facilitates Liver Cancer Progression by Cooperating with PLRG1 to Drive Superenhancer-Mediated Transcription of Cyclin D1.DHX37 RNA 解旋酶通过与 PLRG1 合作驱动细胞周期蛋白 D1 的超级增强子介导转录促进肝癌进展。
Cancer Res. 2022 May 16;82(10):1937-1952. doi: 10.1158/0008-5472.CAN-21-3038.
3
Front Pharmacol. 2025 Apr 28;16:1565738. doi: 10.3389/fphar.2025.1565738. eCollection 2025.
4
Basic Epigenetic Mechanisms.基本表观遗传机制
Subcell Biochem. 2025;108:1-49. doi: 10.1007/978-3-031-75980-2_1.
5
FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects.FBXW7在胃肠道癌症中的研究:从分子机制到治疗前景
Front Pharmacol. 2024 Dec 18;15:1505027. doi: 10.3389/fphar.2024.1505027. eCollection 2024.
6
SE-lncRNAs in Cancer: Classification, Subcellular Localisation, Function and Corresponding TFs.癌症中的SE-lncRNAs:分类、亚细胞定位、功能及相应转录因子
J Cell Mol Med. 2024 Dec;28(24):e70296. doi: 10.1111/jcmm.70296.
7
A novel super-enhancer-related risk model for predicting prognosis and guiding personalized treatment in hepatocellular carcinoma.一种新型的与超级增强子相关的风险模型,用于预测肝细胞癌的预后并指导个体化治疗。
BMC Cancer. 2024 Sep 2;24(1):1087. doi: 10.1186/s12885-024-12874-7.
8
Mechanisms and clinical landscape of N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers.胃肠道癌症中N6-甲基腺苷(m6A)RNA修饰的机制与临床概况
Mol Cell Biochem. 2024 Jul;479(7):1553-1570. doi: 10.1007/s11010-024-05040-x. Epub 2024 Jun 10.
9
Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets.超级增强子在癌症转移中的作用:机制和治疗靶点。
Mol Cancer. 2024 Jun 7;23(1):122. doi: 10.1186/s12943-024-02033-8.
10
Pan-cancer analysis of super-enhancer-induced LINC00862 and validation as a SIRT1-promoting factor in cervical cancer and gastric cancer.超级增强子诱导的LINC00862的泛癌分析及其作为宫颈癌和胃癌中SIRT1促进因子的验证
Transl Oncol. 2024 Jul;45:101982. doi: 10.1016/j.tranon.2024.101982. Epub 2024 May 7.
Super-enhancers modulate interleukin-6 expression and function in cancers.
超级增强子调控癌症中白细胞介素-6的表达及功能。
Transl Cancer Res. 2020 Sep;9(9):5555-5565. doi: 10.21037/tcr-19-2825.
4
Integrated bioinformatics and experiments reveal the roles and driving forces for HSF1 in colorectal cancer.整合生物信息学和实验揭示了热休克因子 1(HSF1)在结直肠癌中的作用和驱动因素。
Bioengineered. 2022 Feb;13(2):2536-2552. doi: 10.1080/21655979.2021.2018235.
5
Genome-wide identification of microRNA targets reveals positive regulation of the Hippo pathway by miR-122 during liver development.全基因组鉴定 microRNA 靶标揭示 miR-122 在肝脏发育过程中对 Hippo 通路的正向调控。
Cell Death Dis. 2021 Dec 14;12(12):1161. doi: 10.1038/s41419-021-04436-7.
6
Super-enhancer-driven lncRNA-DAW promotes liver cancer cell proliferation through activation of Wnt/β-catenin pathway.超级增强子驱动的lncRNA-DAW通过激活Wnt/β-连环蛋白通路促进肝癌细胞增殖。
Mol Ther Nucleic Acids. 2021 Nov 3;26:1351-1363. doi: 10.1016/j.omtn.2021.10.028. eCollection 2021 Dec 3.
7
Transcriptional inhibition by CDK7/9 inhibitor SNS-032 suppresses tumor growth and metastasis in esophageal squamous cell carcinoma.CDK7/9 抑制剂 SNS-032 的转录抑制作用抑制食管鳞状细胞癌的肿瘤生长和转移。
Cell Death Dis. 2021 Nov 5;12(11):1048. doi: 10.1038/s41419-021-04344-w.
8
Genome-wide profiling in colorectal cancer identifies PHF19 and TBC1D16 as oncogenic super enhancers.在结直肠癌中进行全基因组分析,确定 PHF19 和 TBC1D16 为致癌性超级增强子。
Nat Commun. 2021 Nov 4;12(1):6407. doi: 10.1038/s41467-021-26600-5.
9
Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis.Sirtuin 7 超级增强子驱动肝癌发生中的表观基因组重编程。
Cancer Lett. 2022 Jan 28;525:115-130. doi: 10.1016/j.canlet.2021.10.039. Epub 2021 Nov 1.
10
Hepatocyte nuclear factor HNF1A is a potential regulator in shaping the super-enhancer landscape in colorectal cancer liver metastasis.肝细胞核因子 HNF1A 是塑造结直肠癌肝转移超级增强子景观的潜在调节因子。
FEBS Lett. 2021 Dec;595(24):3056-3071. doi: 10.1002/1873-3468.14219. Epub 2021 Nov 22.